Cite
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose.
MLA
Jessen, Bart A., et al. “Correction to: An IQ Consortium Analysis of Starting Dose Selection for Oncology Small Molecule First‑in‑patient Trials Suggests an Alternative NOAEL‑based Method Can Be Safe While Reducing Time to the Recommended Phase 2 Dose.” Cancer Chemotherapy & Pharmacology, vol. 94, no. 3, Sept. 2024, p. 1. EBSCOhost, https://doi.org/10.1007/s00280-023-04595-8.
APA
Jessen, B. A., Cornwell, P., Redmond, S., Visalli, T., Lemper, M., Bunch, T., & Hart, T. (2024). Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose. Cancer Chemotherapy & Pharmacology, 94(3), 1. https://doi.org/10.1007/s00280-023-04595-8
Chicago
Jessen, Bart A., Paul Cornwell, Sean Redmond, Thomas Visalli, Marie Lemper, Todd Bunch, and Timothy Hart. 2024. “Correction to: An IQ Consortium Analysis of Starting Dose Selection for Oncology Small Molecule First‑in‑patient Trials Suggests an Alternative NOAEL‑based Method Can Be Safe While Reducing Time to the Recommended Phase 2 Dose.” Cancer Chemotherapy & Pharmacology 94 (3): 1. doi:10.1007/s00280-023-04595-8.